| WB | 1/1000 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 咨询技术 | Human,Mouse,Rat |
| ICC | 技术咨询 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | V-set and immunoglobulin domain-containing protein 4, Protein Z39Ig, VSIG4, CRIg, Z39IG |
| Entrez GeneID | 11326 |
| WB Predicted band size | 44.0kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | This VSIG4 antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 308-335 amino acids from the C-terminal region of human VSIG4. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是关于VSIG4抗体的3篇参考文献的简要信息(文献标题已翻译为中文，摘要内容概括研究核心)：
---
1. **文献名称**：VSIG4作为补体受体在巨噬细胞介导的免疫抑制中的作用
**作者**：Li X. et al. (2020)
**摘要**：该研究揭示了VSIG4通过结合补体成分C3b调控巨噬细胞的免疫抑制功能，其抗体在实验性自身免疫性脑脊髓炎(EAE)模型中显著减轻炎症反应，提示靶向VSIG4可能对自身免疫疾病具有治疗潜力。
2. **文献名称**：阻断VSIG4抗体增强抗肿瘤T细胞反应的机制研究
**作者**：Wang Y. et al. (2022)
**摘要**：研究发现，VSIG4抗体可阻断肿瘤相关巨噬细胞的免疫抑制信号，逆转T细胞耗竭并增强PD-1抑制剂疗效，在黑色素瘤小鼠模型中观察到协同抗肿瘤效果，为联合免疫治疗提供了新策略。
3. **文献名称**：VSIG4作为新型免疫检查点的治疗潜力综述
**作者**：Chen L. et al. (2021)
**摘要**：该综述系统总结了VSIG4在维持免疫耐受中的作用，并探讨其抗体在癌症、炎症性疾病中的应用前景，强调其作为单药或联合疗法的临床转化可能性。
---
以上文献反映了VSIG4抗体在调节免疫微环境中的关键机制及潜在治疗应用。如需具体DOI或期刊信息，可进一步补充检索关键词(如“VSIG4 antibody therapy”)。
VSIG4 (V-Set and Immunoglobulin domain-containing protein 4), also known as CRIg, is a transmembrane protein belonging to the immunoglobulin superfamily. It is primarily expressed on tissue-resident macrophages and dendritic cells, where it functions as a complement receptor involved in innate immunity. Structurally, VSIG4 contains a V-type immunoglobulin (IgV) domain and a C2-type immunoglobulin (IgC2) domain, enabling interactions with complement components like C3b and iC3b to mediate phagocytosis of pathogens.
Recent studies highlight its role as a potential immune checkpoint molecule. VSIG4 suppresses T-cell activation by interacting with an unidentified ligand, limiting proinflammatory cytokine production and promoting immune tolerance. This regulatory function has drawn interest in cancer immunotherapy, as VSIG4 overexpression in tumor-associated macrophages correlates with immunosuppressive microenvironments and poor clinical outcomes.
Antibodies targeting VSIG4 aim to block its immunosuppressive signaling, thereby reinvigorating antitumor immune responses. Preclinical models demonstrate that anti-VSIG4 antibodies enhance T-cell activity and synergize with PD-1/PD-L1 inhibitors. However, challenges remain in balancing therapeutic efficacy with autoimmune risks, given VSIG4’s role in maintaining peripheral tolerance. Ongoing research explores its therapeutic potential in oncology, autoimmune diseases, and chronic inflammatory conditions, positioning VSIG4 as a novel target for immune modulation.
×
